Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 18.26 SEK -4.85% Market Closed
Market Cap: 852.6m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Moberg Pharma AB (publ)
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Moberg Pharma AB (publ)
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Moberg Pharma AB (publ)
STO:MOB
Total Current Liabilities
kr20.5m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Total Current Liabilities
kr429.8m
CAGR 3-Years
52%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Total Current Liabilities
kr403.3m
CAGR 3-Years
27%
CAGR 5-Years
26%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Total Current Liabilities
kr357.1m
CAGR 3-Years
61%
CAGR 5-Years
77%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Total Current Liabilities
kr36.7m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Total Current Liabilities
kr23.2m
CAGR 3-Years
15%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
836.9m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.61 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Moberg Pharma AB (publ)'s Total Current Liabilities?
Total Current Liabilities
20.5m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Total Current Liabilities amounts to 20.5m SEK.

What is Moberg Pharma AB (publ)'s Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
-36%

Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for Moberg Pharma AB (publ) have been -36% over the past three years .

Back to Top